What Happened? Shares of medical device company DexCom (NASDAQ:DXCM) jumped 3.7% in the afternoon session after it rebounded ...

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ...

DexCom Inc (DXCM) reports a robust 22% increase in worldwide revenue, driven by expanded CGM access and strategic market ...

DexCom Inc. (NASDAQ:DXCM) is one of the best NASDAQ growth stocks to buy for the next 5 years. On October 15, Truist analyst ...

Over the past five years, diabetes-focused medical device specialist DexCom (NASDAQ: DXCM) has made meaningful progress on several fronts. The company launched new products in the continuous glucose ...

Motorola Solutions (MSI) accelerated its sell-off last week after falling by 5.85% on Oct. 31. Shares peaked at $507.82 in the year and closed at $406.71. The company posted a 7.5% Y/Y rise in revenue ...

DexCom’s GAAP operating income reached $242.5 million or 20.1% of revenue, representing a significant improvement of 480 basis points compared to the third quarter of 2024.

After a report was released by short-sellers last month highlighting threats facing the company, shares in DexCom (NASDAQ: DXCM) stumbled 14.5% in March, according to S&P Global Market Intelligence.

In addition to Oppenheimer, Dexcom also received a Hold from J.P. Morgan’s Robbie Marcus in a report issued today. However, on the same day, BTIG maintained a Buy rating on Dexcom (NASDAQ: DXCM). The ...

Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.